Porvair acquires J.G. Finneran Associates
![](/46/pdcnewsitem/04/58/23/porvair%20sciences.png)
Finneran bringing glass, plastics and assembly manufacturing capabilities and strong US distribution.
Porvair Sciences is pleased to welcome J.G. Finneran Associates into the Porvair family following its acquisition by Porvair plc.
Based in Vineland, New Jersey, J.G. Finneran designs, manufactures and distributes specialist laboratory consumables including vials, filters, microplates, closures and ancillary products. Finneran products clearly complement the biotechnology and chromatography product lines of Porvair Sciences and the combined product ranges will provide an enhanced offering to all customers.
There is a good fit and synergy between the J.G. Finneran and Porvair Sciences businesses with Finneran bringing glass, plastics and assembly manufacturing capabilities as well as strong US distribution. This complements the strong UK-based manufacturing and distribution capabilities of Porvair Sciences and together the businesses have a broad product offering for chromatography, sample preparation and environmental laboratories.
Both companies have a strong history of innovation and this will continue with emphasis on developing unique solutions for sample preparation in biotechnology and chromatography applications based around their core vial, microplate and filtration capabilities. Customers will benefit from Porvair Sciences products being manufactured, stocked and distributed from J.G. Finneran’s facility in Vineland USA, as well as Finneran products being distributed from Wrexham UK. This is an exciting time in the development of both companies who look forward to achieving significant growth in the international scientific laboratory marketplace.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance